New hope for patients with aggressive, Treatment-Resistant leukemia
NCT ID NCT05986240
Summary
This early-stage study is testing the safety and initial effectiveness of a new drug called Danvatirsen, first by itself and then combined with an existing drug, Venetoclax. It is for adults with advanced forms of blood cancer (MDS or AML) that have returned or not responded to all standard treatments. The main goal is to find the safest and most effective dose for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M.D. Anderson Cancer Center, Department of Leukemia
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.